Insights
Our team delivers real-world insights and strategic expertise that go beyond industry standards, backed by extensive experience as both payers and manufacturers.
Unlocking the Power of Value-Based Contracts: Applying Operational Lessons from Gene Therapy to Broader Therapeutic Markets
Cell and gene therapy (CGT) is redefining value-based care with outcomes-driven contracts, helping payers balance access and sustainability as they reimburse based on real-world results.
Weighing the Costs and Benefits of GLP-1 Drugs: A Case for Aligning Value with Outcomes
The rise of GLP-1 receptor agonists like semaglutide and tirzepatide offers significant breakthroughs in obesity treatment, but also poses substantial economic challenges. As we integrate obesity management into healthcare, a shift to value-based medicine should tie treatment prices to real outcomes, ensuring long-term benefits for patients and society.
Aligning Oncology Drug Prices With Value: The Case for Innovative Pricing Models
The rapid innovation in cancer treatment has improved patient outcomes, but high costs and limited benefits for many therapies pose significant challenges. As oncology therapies become more personalized, managing their financial impact remains crucial.
Performance guarantees: Leveraging technology to enable insights into reimbursement opportunities
The 2024 SIIA Forum emphasized the financial risks payers and reinsurers face with costly therapies like CGTs, oncology treatments, and GLP-1 agonists. Insurers must now balance patient access with financial sustainability.
Accelerating the Transition to Value in Value-Based Contracting
As healthcare shifts to value-based models, pharmaceuticals lag behind, despite being the most utilized health benefit. However, technological and data management advancements in recent years have effectively removed many operational barriers.